Lei Jin
Agios Pharmaceuticals
5 Papers
Lei Jin is an academic researcher from Agios Pharmaceuticals. The author has contributed to research in topics: IDH1 & Cellular differentiation. The author has an hindex of 4, co-authored 5 publications. Previous affiliations of Lei Jin include Wellesley College.
Chat about Author
Papers
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
Katharine E. Yen,Jeremy Travins,Fang Wang,Muriel D. David,Muriel D. David,Erin Artin,Kimberly Straley,Anil K. Padyana,Stefan Gross,Byron DeLaBarre,Erica Tobin,Yue Chen,Raj Nagaraja,Sung Choe,Lei Jin,Zenon D. Konteatis,Giovanni Cianchetta,Jeffrey O. Saunders,Francesco G. Salituro,Cyril Quivoron,Cyril Quivoron,Paule Opolon,Olivia Bawa,Véronique Saada,Véronique Saada,Angelo Paci,Sophie Broutin,Olivier Bernard,Olivier Bernard,Stéphane de Botton,Stéphane de Botton,Benoit S. Marteyn,Benoit S. Marteyn,Monika Pilichowska,Yingxia Xu,Cheng Fang,Fan Jiang,Wentao Wei,Shengfang Jin,Lee Silverman,Wei Liu,Hua Yang,Lenny Dang,Marion Dorsch,Virginie Penard-Lacronique,Virginie Penard-Lacronique,Scott A. Biller,Shin-San Michael Su +47 more
TL;DR: It is shown that the targeted inhibitor AG-221 suppresses the mutant IDH2 enzyme in multiple preclinical models and induces differentiation of malignant blasts, supporting its clinical development.
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma
Zenon D. Konteatis,Erin Artin,Brandon Nicolay,Kimberly Straley,Anil K. Padyana,Lei Jin,Yue Chen,Rohini Narayaraswamy,Shuilong Tong,Feng Wang,Ding Zhou,Cui Dawei,Zhenwei Cai,Zhiyong Luo,Cheng Fang,Huachun Tang,Xiaobing Lv,Raj Nagaraja,Hua Yang,Shinsan M. Su,Zhihua Sui,Lenny Dang,Katharine E. Yen,Janeta Popovici-Muller,Paolo Codega,Carl Campos,Ingo K. Mellinghoff,Scott A. Biller +27 more
TL;DR: Vorasidenib represents a novel dual mIDH1/2 inhibitor that penetrates the brain of several preclinical species and inhibits 2-HG production in glioma tissue by >97% in an orthotopicglioma mouse model.
137
Structure and inhibition mechanism of the catalytic domain of human squalene epoxidase.
Anil K. Padyana,Stefan Gross,Lei Jin,Giovanni Cianchetta,Rohini Narayanaswamy,Feng Wang,Rui Wang,Cheng Fang,Xiaobing Lv,Scott A. Biller,Lenny Dang,Christopher E. Mahoney,Nelamangala Nagaraja,David Pirman,Zhihua Sui,Janeta Popovici-Muller,Gromoslaw A. Smolen +16 more
TL;DR: The first three-dimensional high-resolution crystal structures of the human SQLE catalytic domain alone and bound with small molecule inhibitors are presented, which will facilitate the development of next-generation SQLE inhibitors.
68
Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP Deletion
Zenon D. Konteatis,Jeremy Travins,Stefan Gross,Katya Marjon,Amelia Barnett,Everton Mandley,Brandon Nicolay,Raj Nagaraja,Yue Chen,Yabo Sun,Zhixiao Liu,Jie Yu,Ye Zhixiong,Fan Jiang,Wentao Wei,Cheng Fang,Yi Gao,Peter Kalev,Marc L. Hyer,Byron DeLaBarre,Lei Jin,Anil K. Padyana,Lenny Dang,Joshua Murtie,Scott A. Biller,Zhihua Sui,Kevin Marks +26 more
TL;DR: AG-270 as mentioned in this paper is a MAT2A inhibitor that is substrate noncompetitive and inhibit the release of S-adenosyl methionine (SAM) from the enzyme's active site.
50
Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase.
Gabrielle McDonald,Victor Chubukov,John Coco,Kevin Truskowski,Rohini Narayanaswamy,Sung Choe,Mya Steadman,Erin Artin,Anil K. Padyana,Lei Jin,Sebastien Ronseaux,Charles Locuson,Zi Peng Fan,Tabea Erdmann,Alan Mann,Sebastian Hayes,Mark Fletcher,Kavitha Nellore,Siva Sanjeeva Rao,Hosahalli Subramanya,K. Satish Reddy,Sunil Kumar Panigrahi,Thomas Antony,Sreevalsam Gopinath,Zhihua Sui,Nelamangala Nagaraja,Lenny Dang,Georg Lenz,Jonathan Hurov,Scott A. Biller,Josh Murtie,Kevin Marks,Danielle Ulanet +32 more
TL;DR: Findings support targeting of DHODH in lymphoma and other hematologic malignancies and suggest combination strategies aimed at interfering with DNA-damage response pathways.